Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau

BACKGROUND: Olaparib has been approved as an active and maintenance therapy for patients with platinum‐sensitive, BRCA‐mutated high‐grade serous ovarian cancer (SOC). However, the efficacy and safety data is lack among Chinese ovarian cancer patients. AIM: This real‐world study aimed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yabing, Chen, Hongtao, Huang, Yaobin, Hu, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Study Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941423/
https://www.ncbi.nlm.nih.gov/pubmed/32721133
http://dx.doi.org/10.1002/cnr2.1180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941423/
https://www.ncbi.nlm.nih.gov/pubmed/32721133
http://dx.doi.org/10.1002/cnr2.1180

Ejemplares similares